Steven Sarkisian, Jr., MD, of Oklahoma Eye Surgeons, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about the second-generation iDose implant, which contains twice as much medicine. Dr. Sarkisian said the 3-month results are promising.
Steven Sarkisian, Jr., MD:
Hi, I’m Steve Sarkisian, MD, founder and CEO of Oklahoma Eye Surgeons in Oklahoma City. I’m here at ASCRS 2026 in Washington DC and had an opportunity to present about the second-generation iDose implant, the travoprost sustained-release implant that will eventually be called TREX. Really cool how we were able to do the first ones of these. Short study, 10 patients. The second-generation travoprost sustained-release implant has twice as much medicine. The implant is the same size, but it has twice as much medicine. We’re expecting it to last almost twice as long.
However, that’s not what we looked at in this study. In this study, we simply looked at efficacy out to 3 months because that’s one of the things that the FDA wants to know is safety and efficacy out to 3 months. As expected, we noted significant efficacy at every time point, anywhere from a 35 to 44% drop in IOP and with an average greater than 35% after 3 months.
The other cool thing that is really a remarkable part of this story is that the IOP is 2 mmHg lower with the travoprost implant than with travoprost as a topical eye drop. These 2 treatments are not mutually exclusive. There is a superiority to being treated with an iDose than to be treated with travoprost as an eye drop for multiple of reasons, not just because of all the side effects of topical eye drops, but also because the sustained-release model works better. The IOP is lower with that because it’s right near where it needs to be treating the end organ directly.
These are exciting times, and we’re pressing forward with a larger study with this device, and we’re just thankful to have an opportunity to present it here at ASCRS 2026.
Related Content
